Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ACRS

Aclaris Therapeutics Inc

ACRS

1.00USD-0.02 (-1.96%)Delayed as of 07 Dec 2023, 03:05 pm
Watchlist

Market Summary

USD1.00-0.02
Delayedas of 07 Dec 2023, 03:05 pm
-1.96%

ACRS Stock Price

View Fullscreen

ACRS RSI Chart

ACRS Valuation

Market Cap

72.2M

Price/Earnings (Trailing)

-0.63

Price/Sales (Trailing)

3.37

EV/EBITDA

-7.82

Price/Free Cashflow

-0.79

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

88.29%

EBT Margin

-281.92%

Return on Equity

-58.59%

Return on Assets

-44.69%

Free Cashflow Yield

-126.88%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

21.4M

Revenue Y/Y

-51.19%

Revenue Q/Q

396.63%

ACRS Earnings

Earnings (TTM)

-114.6M

Earnings Y/Y

-46.66%

Earnings Q/Q

1.04%

Price Action

52 Week Range

0.9618.54
(Low)(High)

Last 7 days

14.8%

Last 30 days

-81.6%

Last 90 days

-86.7%

Trailing 12 Months

-93.7%

How does ACRS drawdown profile look like?

ACRS Financial Health

Current Ratio

5.82

ACRS Investor Care

Shares Dilution (1Y)

6.21%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202330.8M31.2M21.4M0
20226.4M6.1M23.5M29.8M
20216.9M6.6M6.8M6.8M
20204.4M5.5M6.0M6.5M
20199.7M6.9M6.8M4.2M
20184.1M6.5M6.9M9.6M
20170001.7M
20160000
201538.0K60.0K82.0K104.0K
201419.8K18.5K17.3K16.0K
201300021.0K

Latest Insider Trading transactions for ACRS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 23, 2023
monahan joseph
sold
-30,460
5.0767
-6,000
chief scientific officer
Sep 06, 2023
balthaser kevin
bought
74,971
7.9
9,490
chief financial officer
Sep 01, 2023
balthaser kevin
acquired
-
-
1,000
chief financial officer
Sep 01, 2023
balthaser kevin
sold (taxes)
-2,251
7.9
-285
chief financial officer
Aug 28, 2023
loerop james
bought
99,958
6.7976
14,705
chief business officer
Aug 21, 2023
monahan joseph
sold
-43,894
7.3158
-6,000
chief scientific officer
Aug 01, 2023
manion douglas j.
sold (taxes)
-43,527
9.81
-4,437
pres and ceo
Aug 01, 2023
manion douglas j.
acquired
-
-
15,575
pres and ceo
Jul 01, 2023
cawkwell gail
sold (taxes)
-56,070
10.37
-5,407
chief medical officer
Jul 01, 2023
cawkwell gail
acquired
-
-
15,000
chief medical officer

1–10 of 50

Which funds bought or sold ACRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-85.8
-10,211,200
1,057,020
-%
Nov 21, 2023
Walleye Capital LLC
reduced
-66.05
-2,747,840
794,340
-%
Nov 21, 2023
Walleye Trading LLC
reduced
-29.36
-256,252
224,159
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
added
241
669,556
1,202,040
0.01%
Nov 15, 2023
MORGAN STANLEY
added
3.89
-5,319,050
11,634,000
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
reduced
-54.51
-605,000
260,000
0.02%
Nov 15, 2023
Tudor Investment Corp Et Al
added
-
-116,793
227,304
-%
Nov 15, 2023
JANE STREET GROUP, LLC
added
8.62
-442,422
1,123,810
-%
Nov 15, 2023
Baker Avenue Asset Management, LP
new
-
233
233
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
1.85
-93,211
191,622
-%

1–10 of 37

Latest Funds Activity

Are funds buying ACRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACRS
No. of Funds

Schedule 13G FIlings of Aclaris Therapeutics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 24, 2023
tang capital partners lp
6.1%
4,338,155
SC 13G
Sep 05, 2023
citadel advisors llc
4.7%
6
SC 13G
Apr 10, 2023
wellington management group llp
11.05%
7,372,601
SC 13G/A
Mar 16, 2023
biotechnology value fund l p
2.7%
1,794,881
SC 13G
Feb 14, 2023
rock springs capital management lp
5.94%
3,961,249
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
2.6%
1,732,725
SC 13G/A
Feb 13, 2023
foresite capital fund iv, l.p.
4.2%
2,808,034
SC 13G/A
Feb 06, 2023
wellington management group llp
8.22%
5,484,013
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
5,087,435
SC 13G/A
Apr 25, 2022
ra capital management, l.p.
7.1%
4,398,453
SC 13G

Recent SEC filings of Aclaris Therapeutics Inc

View All Filings
Date Filed Form Type Document
Nov 24, 2023
SC 13G
Major Ownership Report
Nov 13, 2023
8-K
Current Report
Nov 06, 2023
8-K
Current Report
Nov 06, 2023
10-Q
Quarterly Report
Oct 25, 2023
4
Insider Trading
Oct 23, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
8-K
Current Report
Sep 07, 2023
4
Insider Trading
Sep 05, 2023
SC 13G
Major Ownership Report
Sep 05, 2023
4
Insider Trading

Peers (Alternatives to Aclaris Therapeutics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
163.2B
29.6B
12.94% -16.78%
27.58
5.52
-5.39% -12.54%
43.3B
3.6B
23.29% 25.56%
52.66
12.08
7.43% 22.86%
37.8B
7.0B
20.00% -14.74%
33.37
5.41
5.03% -14.68%
15.1B
9.3B
0.81% -9.39%
19.81
1.63
-9.69% -38.22%
11.8B
2.4B
-0.06% 41.10%
-41.76
4.9
19.99% 60.62%
MID-CAP
10.3B
4.2B
10.65% -4.98%
21.68
2.44
11.49% 8.84%
8.5B
1.8B
3.40% 36.73%
31.26
4.79
29.62% 20.49%
6.9B
988.7M
34.39% 49.28%
-13.8
6.97
27.41% 8.51%
3.9B
919.1M
13.84% 16.34%
-146.51
4.24
73.02% -172.93%
3.0B
535.8M
-7.21% -48.01%
-7.02
5.66
24.38% 26.34%
SMALL-CAP
522.0M
297.1M
48.77% -26.91%
-5.77
1.76
-6.74% -21.60%
72.2M
21.4M
-81.57% -93.66%
-0.63
3.37
-8.80% -39.66%
28.4M
9.2M
-30.15% -40.72%
-1.61
3.09
16.43% 48.38%
14.3M
16.1M
27.59% -22.38%
-2.03
0.89
-8.51% 41.77%
144.4K
-
-82.76% -93.43%
0
0.76
-57.78% -93.13%

Aclaris Therapeutics Inc News

Latest updates
InvestorsObserver07 Dec 202301:26 pm7 hours ago
The DBT News06 Dec 202303:51 pm29 hours ago
SETE News06 Dec 202303:08 pm29 hours ago
Investing.com UK06 Dec 202301:32 pm31 hours ago
finanznachrichten.de06 Dec 202310:24 am34 hours ago
Nasdaq06 Dec 202310:03 am34 hours ago
Marketscreener.com05 Dec 202309:03 pm47 hours ago
InvestorsObserver21 Nov 202302:55 pm16 days ago
InvestorsObserver16 Nov 202308:00 am21 days ago
英为财情 Investing.com14 Nov 202308:00 am23 days ago
Investing.com Türkiye14 Nov 202308:00 am23 days ago
BioWorld Online13 Nov 202304:00 pm24 days ago
Yahoo Finance13 Nov 202308:00 am24 days ago
Investing.com13 Nov 202308:00 am24 days ago

Financials for Aclaris Therapeutics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue396.6%9,282,0001,869,0002,528,0007,753,00019,018,0001,528,0001,453,0001,501,0001,659,0001,824,0001,777,0001,580,0001,449,0002,046,0001,407,0001,095,000983,000886,0001,263,0003,669,0001,118,000
Cost Of Revenue-18.6%848,0001,042,000808,000877,000923,0001,068,0001,155,0001,149,0001,099,0001,263,0001,202,0001,286,0001,189,0001,389,0001,269,0001,027,500826,000994,0001,207,0001,190,0001,067,000
Gross Profit--------------------160,000435,000
Costs and Expenses21.3%40,859,00033,684,00032,446,00036,832,00039,892,00022,522,00020,360,00024,394,00021,954,00019,830,00030,306,00015,140,00011,914,00013,427,00016,913,00013,058,00023,847,00055,656,00028,314,00013,283,50022,460,000
Operating Expenses--------------------39,198,00033,885,000
  S&GA Expenses-14.7%7,091,0008,317,0008,790,0007,146,0005,813,0006,075,0006,099,0006,943,0005,979,0005,870,0004,827,0004,898,5003,859,0005,572,0006,200,0006,056,0006,838,0007,469,0007,464,00013,884,50063,000
  R&D Expenses-5.5%23,876,00025,275,00022,587,00021,072,00023,656,00018,779,00014,306,00014,102,00013,976,0007,897,0007,838,0008,955,5006,240,0006,466,0007,677,00010,825,50016,183,00017,519,00019,643,00018,710,50015,189,000
EBITDA Margin----2.79-2.89--14.67-13.99-13.30---7.34-7.72-18.58-19.96-11.63-25.34-10.67-10.65---
EBT Margin----2.82-2.92--14.80-14.12-13.44---7.49-7.92-18.93-20.53-12.14-26.86-11.27-11.14---
Net Income1.0%-29,261,000-29,569,000-28,160,000-27,635,000-19,952,000-20,532,000-18,789,000-22,804,000-21,146,000-18,161,000-28,754,000-13,173,000-10,659,000-11,597,000-15,586,000-18,594,000-55,319,000-49,876,000-37,565,000-38,551,000-32,740,000
Net Income Margin100.0%--3.38-3.12-2.92-3.49-13.56-12.57-13.44-11.88-10.67-9.37-7.87-9.41-18.28-14.91-38.17-----
Free Cashflow100.0%--20,885,000-26,906,000-19,220,000-7,967,000-19,852,000-21,133,000-17,275,000-10,662,000-12,247,000-12,240,000-8,865,000-12,454,000-10,838,000-6,929,000-20,656,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-7.3%21823623025526827822725126328816171.0072.0085.0097.0098.00160217253276176
  Current Assets-7.4%12313318423225725919120520624113557.0058.0071.0083.0084.00145138157179146
    Cash Equivalents25.3%39.0031.0045.0045.0062.0068.0036.0027.0054.0011335.0022.0025.0033.0054.0036.0030.0032.0034.0057.0027.00
  Inventory-----------------0.000.001.001.001.00
  Net PPE-7.1%2.002.002.001.001.001.001.001.001.001.001.002.002.002.002.002.003.004.004.002.004.00
  Goodwill----------------19.00--19.0019.0019.00
Liabilities11.0%62.0056.0053.0057.0048.0042.0046.0054.0047.0054.0049.0033.0031.0036.0039.0028.0075.0080.0071.0060.0030.00
  Current Liabilities19.7%27.0023.0018.0022.0020.0016.0017.0023.0018.0015.0015.0015.0013.0018.0021.0022.0039.0043.0036.0027.0022.00
  Long Term Debt----------11.0011.0011.0011.0011.0011.00-30.0030.0030.0030.00-
Shareholder's Equity-13.0%15618017719822023618019721723411238.0041.0049.0058.0070.0085.00137182215146
  Retained Earnings-4.0%-769-740-710-682-654-634-614-595-572-551-533-504-491-480-469-453-434-379-329-292-253
  Additional Paid-In Capital0.6%927921888881876872795793789785646542532530527524520517512507400
Shares Outstanding0.1%71.0071.0067.0067.0067.0066.0061.0061.0061.0054.0050.0045.0042.0042.0042.0041.0041.0041.0041.0033.0031.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-18.9%-24,557,000-20,654,000-26,353,000-19,115,000-7,817,000-19,666,000-20,969,000-17,075,000-10,606,000-12,221,000-12,232,000-8,857,000-12,150,000-10,821,000-6,805,000-20,390,000-23,359,000-21,378,000-31,318,000-27,248,000-29,858,000
  Share Based Compensation-8.8%5,948,0006,522,0006,806,0004,813,0004,188,0003,692,0002,346,0003,851,0003,702,0003,832,0002,675,0002,504,0001,941,0003,309,0003,453,0003,181,0003,320,0004,814,0004,862,0004,956,0004,707,000
Cashflow From Investing265.5%32,534,000-19,662,00025,798,0002,702,0001,217,000-21,223,00029,932,000-9,176,000-37,672,000-45,470,000-75,314,000-2,305,0005,237,000-10,487,00013,942,00056,438,00021,673,00018,952,0008,616,000-70,506,00010,394,000
Cashflow From Financing-Infinity%-87,000--37,000-11,00072,811,00030,000-2,000-11,567,000135,871,000100,750,0007,829,000-278,000-97,00010,918,000-30,009,000-70,000-117,000-120,000128,183,00019,000

ACRS Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenue$ 9,282$ 19,018$ 13,679$ 21,999
Costs and expenses:    
Cost of revenue8489232,6983,146
Research and development23,87623,65671,73856,741
General and administrative7,0915,81324,19817,987
Licensing7,3447,3008,9557,300
Revaluation of contingent consideration1,7002,200(600)(2,400)
Total costs and expenses40,85939,892106,98982,774
Loss from operations(31,577)(20,874)(93,310)(60,775)
Other income, net2,3169226,3201,502
Net loss$ (29,261)$ (19,952)$ (86,990)$ (59,273)
Net loss per share, basic$ (0.41)$ (0.30)$ (1.25)$ (0.92)
Net loss per share, diluted$ (0.41)$ (0.30)$ (1.25)$ (0.92)
Weighted average common shares outstanding, basic70,807,93466,675,33769,452,49564,718,008
Weighted average common shares outstanding, diluted70,807,93466,675,33769,452,49564,718,008
Other comprehensive loss:    
Unrealized loss on marketable securities, net of tax of $0$ (18)$ (139)$ (232)$ (1,241)
Total other comprehensive loss(18)(139)(232)(1,241)
Comprehensive loss(29,279)(20,091)(87,222)(60,514)
Contract research    
Revenues:    
Total revenue7051,0902,4693,529
Licensing    
Revenues:    
Total revenue$ 8,57717,898$ 11,21018,378
Other    
Revenues:    
Total revenue $ 30 $ 92

ACRS Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 39,040$ 45,277
Short-term marketable securities64,012172,294
Accounts receivable, net346484
Prepaid expenses and other current assets19,67013,495
Total current assets123,068231,550
Marketable securities83,94412,242
Property and equipment, net1,7641,099
Intangible assets6,9176,973
Other assets2,6612,732
Total Assets218,354254,596
Current liabilities:  
Accounts payable9,64810,351
Accrued expenses15,1608,701
Current portion of lease liabilities310684
Discontinued operations2,2022,202
Total current liabilities27,32021,938
Other liabilities1,8341,570
Contingent consideration32,50033,100
Deferred tax liability367367
Total liabilities62,02156,975
Commitments and contingencies (Note 14)
Stockholders' Equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.00001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 70,818,954 and 66,688,647 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively11
Additional paid-in capital926,766880,832
Accumulated other comprehensive loss(1,129)(897)
Accumulated deficit(769,305)(682,315)
Total stockholders' equity156,333197,621
Total liabilities and stockholders' equity$ 218,354$ 254,596
ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
 CEO
 WEBSITEwww.aclaristx.com
 EMPLOYEES100

Aclaris Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aclaris Therapeutics Inc? What does ACRS stand for in stocks?

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclaris Therapeutics Inc (ACRS)?

As of Wed Dec 06 2023, market cap of Aclaris Therapeutics Inc is 72.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart. The fair value of Aclaris Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aclaris Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aclaris Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

What is Aclaris Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, ACRS's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 3.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.